Scientific exchange · Dr. Gabriel Yamamoto

01 Apr 2026 · In person · Dr. Gabriel Yamamoto, Christie NHS Foundation Trust · MSL Dr. Anna Becker · Nephrada

ReviewedManualENG-0154—

Capture insight from this engagement

Location: Christie NHS Foundation Trust
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Treatment burden and fatigue
APRIL pathway mechanism
eGFR slope interpretation

Scientific content used

NPH mechanism-of-action deck

Questions raised

Is there any data on APRIL inhibition in FSGS?

Notes

Scientific exchange with academic nephrologist at Christie NHS Foundation Trust. Discussed treatment burden and fatigue, april pathway mechanism, egfr slope interpretation.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0154

Audit history (0)

All create, update and approval events for this record

No audit events in sample data